Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, open-label study in stable patients switched from typical and atypical oral antipsychotics

被引：0
|
作者：
Cetin, M [1 ]
Ebrinc, S [1 ]
Basoglu, C [1 ]
Semiz, UB [1 ]
Gunay, H [1 ]
Iyisoy, MS [1 ]
Ergun, BM [1 ]
Gunes, C [1 ]
Sahan, A [1 ]
Oguz, M [1 ]
Noyan, O [1 ]
机构：
[1] Gulhane Haydarpasa Training Hosp, Dept Psychiat, Istanbul, Turkey
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2005年 / 15卷
关键词：
D O I：
10.1016/S0924-977X(05)80287-1
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S134 / S135
页数：2
相关论文
共 50 条
  • [21] The risk for readmission in schizophrenia patients treated with long-acting injectable (typical or atypical) versus oral antipsychotics
    Onn, R.
    Krivoy, A.
    Weizman, A.
    Hochman, E.
    Valevski, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2015, 25 : S494 - S494
  • [22] Efficacy and safety of risperidone long-acting injectable in stable psychotic patients previously treated with oral risperidone
    Schmauss, Max
    Sacchetti, Emilio
    Kahn, Jean-Pierre
    Medori, Rossella
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2007, 22 (02) : 85 - 92
  • [23] LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF RISPERIDONE LONG-ACTING INJECTABLE AND ORAL ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS: TWO YEAR NATURALISTIC STUDY
    Lbach, Bernd
    Rabinowitz, Jonathan
    Schreiner, Andreas
    Hargarter, Ludger
    Diekamp, Bettina
    SCHIZOPHRENIA RESEARCH, 2010, 117 (2-3) : 527 - 527
  • [24] LONG-TERM SAFETY, TOLERABILITY AND EFFICACY OF RISPERIDONE LONG-ACTING INJECTABLE AND ORAL ATYPICAL ANTIPSYCHOTICS IN SCHIZOPHRENIC PATIENTS: TWO YEAR NATURALISTIC STUDY
    Ibach, B.
    Rabinowitz, J.
    Schreiner, A.
    Hargarter, L.
    Diekamp, B.
    EUROPEAN PSYCHIATRY, 2010, 25
  • [25] EFFICACY OF LONG-ACTING INJECTABLE RISPERIDONE IN DELUSIONAL DISORDER: AN OPEN-LABEL, NATURALISTIC AND PROSPECTIVE STUDY
    Gonzalez Rodriguez, A.
    Molina Andreu, O.
    Imaz Gurrutxaga, M. L.
    Pons Villanueva, A.
    EUROPEAN PSYCHIATRY, 2012, 27
  • [26] Switching forensic schizophrenia outpatients from long-acting injectable antipsychotics to olanzapine: An open-label naturalistic study
    Bourget, D
    Labelle, A
    Boulay, LJ
    Tessier, P
    Ellis, J
    SCHIZOPHRENIA RESEARCH, 2004, 67 (01) : 160 - 161
  • [27] Risperidone Long-Acting Injection: Safety and Efficacy in Elderly Patients with Schizophrenia
    Catalan, Rosa
    Penades, Rafael
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2011, 3 : 95 - 105
  • [28] Efficacy and tolerability of long-acting risperidone in patients previously treated with opal atypical antipsychotics
    Schreiner, A
    Moeller, HJ
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 96 - 97
  • [29] A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea
    Lee, Nam Young
    Kim, Se Hyun
    Cho, Seong Jin
    Chung, Young-Cho
    Jung, In Kwa
    Kim, Chang Yoon
    Kim, Duk Ho
    Lee, Dong Geun
    Lee, Yo Han
    Lim, Weon Jeong
    Na, Young Suk
    Shin, Sang Eun
    Woo, Jong-Min
    Yoon, Jin Sang
    Yoon, Bo-Hyun
    Ahn, Yong Min
    Kim, Yong Sik
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2014, 29 (05) : 279 - 287
  • [30] Switching from other second generation antipsychotics to zotepine in schizophrenic patients: an 12-week open-label study
    Chen, J. Y.
    Chen, T. T.
    Lin, C. C.
    Bai, Y. M.
    Wu, B. J.
    Hung, C. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S416 - S417
12345